Barclays raised the firm’s price target on Abivax (ABVX) to $148 from $142 and keeps an Overweight rating on the shares. The firm says the “clean” Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout in late Q2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax Posts 2025 Results, Confirms Phase 3 Ulcerative Colitis Timeline and Expands Leadership Team
- – Abivax SA American Depositary Shares options imply 8.3% move in share price post-earnings
- U.S. Chess Champion Hikaru Stays Ahead of the S&P Thanks to Tech, Oil and Health Stocks
- Abivax SA Sponsored ADR (ABVX) Q4 Earnings Cheat Sheet
- Abivax initiated with a Buy at Jefferies